HIM
NBIX icon

Hillsdale Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Hillsdale Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,760
Closed -$656K – 656
2024
Q1 		$656K Sell
4,760
-50
-1% -$6.83K 0.05% 249
2023
Q4 		$634K Buy
+4,810
New +$554K 0.05% 235
2023
Q3 		– Sell
-4,340
Closed -$409K – 621
2023
Q2 		$409K Hold
4,340
– – 0.04% 288
2023
Q1 		$439K Buy
4,340
+400
+10% +$41.6K 0.04% 344
2022
Q4 		$471K Buy
3,940
+3,800
+2,714% +$445K 0.04% 362
2022
Q3 		$15K Hold
140
– – ﹤0.01% 488
2022
Q2 		$14K Buy
+140
New +$12.9K ﹤0.01% 483
2013
Q4 		– Sell
-3,900
Closed -$44K – 568
2013
Q3 		$44K Buy
+3,900
New +$53.6K 0.01% 422

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Hillsdale Investment Management's NBIX Position: Q2 2024 in Review

Hillsdale Investment Management sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 4,760 shares — an estimated $656K sold.

Hillsdale Investment Management first reported a position in NBIX in Q3 2013 and held it in 8 quarters. The position peaked at $656K in Q1 2024. 595 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • Hillsdale Investment Management reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • Hillsdale Investment Management sold 4,760 Neurocrine Biosciences shares in Q2 2024, an estimated $656K.
  • Hillsdale Investment Management first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 8 quarters.
  • Hillsdale Investment Management's Neurocrine Biosciences position peaked at $656K in Q1 2024.
  • 595 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Hillsdale Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.